Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taladegib + Chemo in Extensive-Stage SCLC
NCT01722292Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of taladegib in small cell lung cancer (SCLC), sponsored by Eli Lilly and Company. Started Jan 2013; status: terminated.
02
Drugs
taladegib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01722292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01722292.